✦ LIBER ✦

6522 POSTER EGFR mutations and response to TKIs therapy in NSCLC patients pre-treated with chemotherapy

✍ Scribed by Crinó, L.; Ludovini, V.; Pistola, L.; Floriani, I.; Betti, M.; Chiari, R.; Giuffrida, D.; Scuderi, C.; Tofanetti, F.R.; Tonato, M.

Book ID: 122484128
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 57 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(07)71350-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9154 Clinical outcomes in patients with

9154 Clinical outcomes in patients with EGFR mutations: pooled analysis of NSCLC patients treated with either an EGFR TKI or chemotherapy

✍ Paz-Ares, L.; Soulières, D.; Klughammer, B.; Melezínek, I.; Moecks, J.; Keil, L. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Overcoming resistance to first generatio

Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient

✍ Pircher, A.; Manzl, C.; Fiegl, M.; Popper, H.; Pirker, R.; Hilbe, W. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 936 KB

128PD EGFR, KRAS, PIK3CA MUTATIONS AND R

128PD EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS

✍ Crinò, L.; Pistola, L.; Bianconi, F.; Chiari, R.; Meacci, M.; Colella, R.; Giuff 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB

9162 EGFR, KRAS, PIK3CA mutations and re

9162 EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients

✍ Chiari, R.; Ludovini, V.; Bianconi, F.; Pistola, L.; Colella, R.; Mameli, M.; Gi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

The Impact of EGFR T790M Mutations and B

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

✍ Costa, C.; Molina, M. A.; Drozdowskyj, A.; Gimenez-Capitan, A.; Bertran-Alamillo 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 651 KB